posted
wow, I see no one is posting on this thread. By lookin' at the way it traded on friday, thiis could be a big gainer on monday. There was buying pressure all day leading to a nice uptrend and then some usual fri. profit taking at eod. It'll go up strong on mon. imo, I;m in with 30k and holding.
Posts: 4071 | Registered: Dec 2005
| IP: Logged |
posted
Fluff PR it might help get some more attention... will try to get back in it this morning...
NORTHWEST BIOTHERAPEUTICS INC (U-NWBT) - News Release Northwest Biotherapeutics to Present at the CE Unterberg, Towbin Life Sciences Conference
2006-10-23 08:02 ET - News Release
BOTHELL, Wash., Oct. 23 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics announced today that Alton Boynton, Ph.D., Company President, will present an update on the Company's progress over the last six months, including ongoing long-term survival data from the Company's clinical trials for Glioblastome multiforme. The presentation will take place Monday, October 30th at 8:30 AM Eastern Time at the CE Unterberg, Towbin Life Sciences Conference. The conference is being held at the Palace Hotel in New York City.
The presentation will be webcast live and available for replay for 90 days from the Northwest Biotherapeutics website, www.nwbio.com under the "Investor and Media" section.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company's three lead product candidates are: DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and CXCR4 a therapeutic monoclonal antibody in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Northwest Biotherapeutics
CONTACT: Lorie Calvo of Northwest Biotherapeutics, +1-425-608-3008